Soria J C, Gauthier L R, Raymond E, Granotier C, Morat L, Armand J P, Boussin F D, Sabatier L
Laboratoire de Radiobiologie et Oncologie, DRR/DSV, CEA, Fontenay-aux-Roses, France.
Clin Cancer Res. 1999 May;5(5):971-5.
The detection of circulating tumor cells and micrometastases may have important therapeutic and prognostic implications. Telomerase is a hallmark of cancer and is absent from normal epithelial cells. The aim of this study was to use telomerase activity as a molecular marker for the detection of cancer cells in blood of patients with breast cancer. Blood samples were collected from 25 women with stage IV breast cancer and 9 healthy volunteers. Peripheral blood mononuclear cells were isolated by using Ficoll/Hypaque. Immunomagnetic beads coated with an epithelial-specific antibody (BerEP4) were used to harvest epithelial cells from peripheral blood mononuclear cells. Telomerase activity was detected in harvested epithelial cells (HECs) using two different telomerase-PCR-ELISA methods. HECs from blood samples of 21 of 25 (84%) patients with breast cancer were telomerase positive. Telomerase activity was undetectable in HECs from the nine healthy volunteers, demonstrating the specificity of the association between telomerase activity in HECs and stage IV breast cancer. Thus, determination of telomerase activity in HECs appears to be a sensitive, specific, and noninvasive approach for detecting circulating epithelial cancer cells in patients with metastatic breast cancer. This method could be of great value in monitoring the cancer cell proliferation during chemotherapy. This study should be now extended to patients with early-stage breast cancer to investigate the role of telomerase expression by HECs and to evaluate its prognostic value.
循环肿瘤细胞和微转移的检测可能具有重要的治疗和预后意义。端粒酶是癌症的一个标志,正常上皮细胞中不存在。本研究的目的是将端粒酶活性作为一种分子标志物,用于检测乳腺癌患者血液中的癌细胞。采集了25例IV期乳腺癌女性患者和9名健康志愿者的血样。使用Ficoll/Hypaque分离外周血单个核细胞。用包被上皮特异性抗体(BerEP4)的免疫磁珠从外周血单个核细胞中收获上皮细胞。使用两种不同的端粒酶-PCR-ELISA方法检测收获的上皮细胞(HECs)中的端粒酶活性。25例乳腺癌患者中有21例(84%)血样中的HECs端粒酶呈阳性。9名健康志愿者的HECs中未检测到端粒酶活性,这证明了HECs中端粒酶活性与IV期乳腺癌之间关联的特异性。因此,检测HECs中的端粒酶活性似乎是一种检测转移性乳腺癌患者循环上皮癌细胞的灵敏、特异且非侵入性的方法。该方法在监测化疗期间癌细胞增殖方面可能具有重要价值。本研究现在应扩展到早期乳腺癌患者,以研究HECs中端粒酶表达的作用并评估其预后价值。